Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability